Maravai LifeSciences (NASDAQ:MRVI) Shares Down 5.8% – Should You Sell?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price fell 5.8% during mid-day trading on Thursday . The stock traded as low as $3.82 and last traded at $3.7130. 140,841 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,063,061 shares. The stock had previously closed at $3.94.

Analysts Set New Price Targets

MRVI has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Wells Fargo & Company increased their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.25.

Maravai LifeSciences Trading Down 6.5%

The firm has a fifty day moving average of $3.53 and a two-hundred day moving average of $3.02. The company has a market cap of $942.28 million, a PE ratio of -4.39 and a beta of 0.33. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The business had revenue of $41.63 million for the quarter, compared to the consensus estimate of $49.02 million. As a group, sell-side analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Insider Transactions at Maravai LifeSciences

In other news, Director Gregory T. Lucier bought 48,528 shares of the stock in a transaction on Monday, December 8th. The shares were acquired at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the purchase, the director directly owned 155,123 shares of the company’s stock, valued at $569,301.41. This trade represents a 45.53% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bernd Brust purchased 216,212 shares of Maravai LifeSciences stock in a transaction dated Thursday, November 13th. The shares were purchased at an average price of $3.25 per share, with a total value of $702,689.00. Following the completion of the transaction, the chief executive officer directly owned 466,771 shares in the company, valued at approximately $1,517,005.75. This represents a 86.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 566,771 shares of company stock worth $1,880,244 in the last three months. 2.11% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRVI. The Manufacturers Life Insurance Company raised its holdings in shares of Maravai LifeSciences by 12.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after acquiring an additional 5,160 shares in the last quarter. Performa Ltd US LLC raised its stake in Maravai LifeSciences by 33.3% in the second quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock valued at $55,000 after purchasing an additional 5,740 shares in the last quarter. Epacria Capital Partners LLC lifted its position in Maravai LifeSciences by 6.8% during the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock valued at $287,000 after purchasing an additional 6,384 shares during the last quarter. Ethic Inc. lifted its position in Maravai LifeSciences by 62.8% during the third quarter. Ethic Inc. now owns 16,951 shares of the company’s stock valued at $49,000 after purchasing an additional 6,540 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Maravai LifeSciences by 121.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock worth $43,000 after buying an additional 9,870 shares in the last quarter. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.